The Development of Ligandrol (LGD-4033): Why It Never Reached Pharmacies
Ligandrol, known in research by the code LGD-4033, is one of the most talked-about selective androgen receptor modulators (SARMs). Despite its popularity in the supplement underground, it has never been approved as a medicine anywhere. Our editorial team traces its development and explains why it remains an unapproved, prohibited investigational compound.
What a SARM is meant to be
SARMs were conceived to capture the muscle-building benefits of androgens while avoiding many of their unwanted effects on the prostate, skin and other tissues. The idea is tissue selectivity: act strongly on muscle and bone, act weakly elsewhere.
Unlike anabolic steroids, most SARMs are non-steroidal molecules. They still bind the androgen receptor, but their chemical structure is different, and researchers hoped this would translate into a cleaner safety profile.
The medical motivation was real. Conditions such as muscle wasting from cancer, aging-related muscle loss (sarcopenia) and recovery from serious illness all lack good treatments. A drug that safely preserved muscle would be genuinely valuable.
Ligandrol was one of several compounds developed to test this concept in humans. Understanding its story requires separating the scientific promise from the marketing hype that later surrounded it.
The origins of LGD-4033
LGD-4033 was discovered by Ligand Pharmaceuticals, whose name inspired the nickname ligandrol. The compound was later licensed to Viking Therapeutics, which has explored SARMs for medical indications.
Chemically, LGD-4033 is a non-steroidal SARM designed to bind the androgen receptor with high affinity and selectivity. In preclinical work it showed the hoped-for pattern: anabolic activity in muscle with comparatively less effect on the prostate in animal models.
These early results were encouraging enough to justify human testing, the stage where many promising compounds reveal their true strengths and weaknesses. Moving into clinical trials is a major and expensive step, taken only for candidates that clear the preclinical bar.
It is important to note that from the outset, LGD-4033 was an investigational drug, a substance being studied, not a finished medicine cleared for public use.
What the clinical trials showed
The key early human study was a phase 1 trial led by Basaria and colleagues, published in 2013. Healthy young men received the compound for 21 days in a placebo-controlled design. The study was designed to assess safety and tolerability, not to promote muscle building.
The trial reported that LGD-4033 was generally well tolerated over this short period and produced a measurable increase in lean body mass compared with placebo. These are the facts as published; we report them as study findings, not as an endorsement.
Importantly, the same study documented hormonal suppression. Even over three weeks, the compound lowered total testosterone, sex hormone binding globulin and other markers, showing that selectivity does not mean the hormonal axis is spared.
Short, small safety studies like this are early steps. They cannot establish whether a drug is safe and effective over the months or years a real treatment would require, nor can they detect rarer harms.
| Stage | What it tests | LGD-4033 status |
|---|---|---|
| Preclinical | Animal efficacy and safety | Completed, encouraging |
| Phase 1 | Human safety, short term | Completed (2013) |
| Phase 2/3 | Efficacy, larger populations | No approved indication |
| Approval | Marketing authorization | Never granted |
Why development stalled
LGD-4033 never progressed to an approved medicine for several reasons common to the SARM field. First, demonstrating long-term efficacy and safety for a chronic condition is a huge, costly undertaking, and many candidates do not justify that investment.
Second, the whole SARM class has faced challenges. The hormonal suppression seen even in short studies, questions about liver effects and the difficulty of proving a real-world clinical benefit have all slowed progress across multiple compounds.
Third, once a compound leaks into the supplement market, as LGD-4033 did, it can complicate legitimate development and attract regulatory scrutiny for reasons unrelated to its medical potential.
The result is that LGD-4033 sits in a limbo familiar to many investigational drugs: interesting early data, no completed late-stage program and no approval. That is the ordinary, unglamorous reality of pharmaceutical research.
Status today and the supplement problem
In the United States, LGD-4033 is not an approved drug and is not a legal dietary supplement ingredient. The FDA has warned that SARMs are being illegally sold in products marketed as supplements and has linked them to serious safety concerns including liver injury.
Independent analyses of products sold as SARMs have repeatedly found mislabeling: wrong compounds, wrong doses or undeclared substances. A consumer buying ligandrol has little assurance of what is actually in the bottle.
LGD-4033 is prohibited at all times by the World Anti-Doping Agency, under the SARM category. Several athletes have recorded doping violations attributed to SARMs, sometimes after taking contaminated supplements unknowingly.
The honest summary is that ligandrol is an experimental compound that never cleared the bar to become a medicine, and that products containing it exist outside both the drug-approval system and the legal supplement framework.
Conclusions of the editorial team
Ligandrol embodies the promise and the limits of the SARM concept: encouraging early data on lean mass, but also clear hormonal suppression and an incomplete development path.
It never reached pharmacies because no completed, large-scale program established it as safe and effective for a defined condition, and because the supplement market complicated its legitimate study.
For consumers, that means ligandrol is not a vetted product but an unapproved compound of uncertain contents and real risk.
Readers may also want our articles on how SARMs differ from anabolic steroids, on contamination in the supplement industry, and on anti-doping testing for research compounds.
References
- Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87–95.
- Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009;12(3):232–240.
- Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004–2010.
- US Food and Drug Administration. FDA warns against using SARMs in body-building products. Consumer safety communication; 2017.
- Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84–94.
